drugset / Trial / NCT01802450
Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Phase 2
Unknown
18 enrolled
PETHEMA Foundation
Bristol-Myers Squibb · collabDynamic Solutions · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Trial try to assess the efficacy of dasatinib in terms of major molecular response rate at 6 months in patients with CP-CML who have achieved complete cytogenetic response without major molecular response after at least 18 months on Imatinib 400/600.
Timeline
- Start
- 2013-03
- Primary completion
- 2015-06
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |